A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab
in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over
250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each
subject's participation will last approximately 4 years.